Padmanee Sharma - Jounce Therapeutics Co-Founder
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Founder
Dr. Padmanee Sharma, M.D. Ph.D. is a cofounder of Jounce Therapeutics and currently serves as scientific director and professor in the departments of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting antitumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including a Department of Defense Idea Development Award, a Cancer Prevention Research Institute of Texas Individual Investigator Award, a National Institute of Health R01 Award and an AACRCRISU2C Immunotherapy dream team grant
| Professional Marks | Ph.D |
| Phone | 857 259 3840 |
| Web | https://jouncetx.com |
Jounce Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Jounce Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Jounce Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Jounce Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Jounce to invest in growth at high rates of return. When we think about Jounce Therapeutics' use of debt, we should always consider it together with cash and equity.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 137 people. Jounce Therapeutics (JNCE) is traded on NASDAQ Exchange in USA and employs 141 people. Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 |
Jounce Therapeutics Leadership Team
Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Drew MD, Founder | ||
| Barbara Duncan, Independent Director | ||
| Luis Diaz, Director | ||
| Robert Schreiber, Founder | ||
| Padmanee MD, Founder | ||
| Drew Pardoll, Co-Founder | ||
| Louis MD, Founder | ||
| Deborah Law, Chief Scientific Officer | ||
| Elizabeth MD, Chief Officer | ||
| Richard Murray, President CEO, Director | ||
| Kimberlee Drapkin, CFO, Treasurer | ||
| Robert Kamen, Independent Director | ||
| Hugh Cole, Chief Business Officer and Head of Corporate Development | ||
| Thomas Gajewski, Co-Founder | ||
| Elizabeth Trehu, Chief Medical Officer | ||
| Robert Tepper, Independent Director | ||
| Perry Karsen, Chairman of the Board | ||
| Padmanee Sharma, Co-Founder | ||
| Cary Pfeffer, Independent Director | ||
| Duncan Higgons, Independent Director | ||
| James Allison, Co-Founder |
Jounce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jounce Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jounce Therapeutics' short interest history, or implied volatility extrapolated from Jounce Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |